Amgen Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +25

Andra AP fonden Has $17.72 Million Stock Position in Amgen Inc. $AMGN

AI-generated analysis

📉 Andra AP fonden cut its Amgen holdings by 18.9% in Q1, reducing its stake to 50,366 shares worth $17.72 million.

📈 Several smaller institutional investors increased their stakes, with Anfield Capital boosting its position by 1,000% to own 77 shares.

💰 Amgen stock opened at $364.17, trading above the 50-day moving average of $348.38 and below the 200-day average of $350.78.

📊 The company has a market cap of $196.55 billion, a P/E ratio of 25.34, and a debt-to-equity ratio of 5.65.

🎯 Analyst consensus target price is $356.62 with an average rating of 'Hold' based on data from MarketBeat.

📉 Daiwa Securities Group lowered its price target to $390 while maintaining an 'outperform' rating in a May 13th report.

📈 UBS Group raised its price target to $420 and assigned a 'buy' rating in a July 13th report.

📉 Argus decreased its price target to $375 but retained a 'buy' rating in a May 20th research note.

💼 SVP Nancy A. Grygiel sold 1,237 shares in May for $400,454, representing a 15% decrease in her personal position.

🏢 Institutional investors collectively own 76.50% of Amgen's outstanding stock.

Bullish Signals
  • UBS Group increased its price target on Amgen from $400 to $420 and upgraded the rating to 'buy' in a July 13th report.
  • Daiwa Securities Group maintains an 'outperform' rating despite lowering its price target, indicating continued confidence in the stock's trajectory.
  • Argus Capital Management retains a 'buy' rating even after reducing its price target, suggesting long-term value potential.
  • Amgen trades above its 50-day moving average of $348.38, indicating short-term bullish momentum relative to recent price action.
  • The company maintains a strong liquidity position with a quick ratio of 1.01 and a current ratio of 1.26.
Risk Factors
  • Andra AP fonden significantly reduced its stake by 18.9% in Q1, selling over 11,000 shares to trim exposure to the biotech giant.
  • Daiwa Securities Group lowered its price target from $410 to $390, reflecting a more cautious near-term outlook.
  • Argus Capital Management decreased its price target from $400 to $375, signaling potential downside pressure or valuation concerns.
  • The stock trades below its 200-day moving average of $350.78, suggesting it may be underperforming over the longer term.
  • SVP Nancy A. Grygiel sold a significant portion of her holdings (15% decrease) in May, potentially indicating insider caution.
Full Analysis
Andra AP fonden reduced its position in Amgen Inc. (NASDAQ: AMGN) by 18.9% during the first quarter, selling 11,734 shares to hold a remaining stake of 50,366 shares valued at $17.72 million. While this major institutional investor trimmed its holdings, several smaller hedge funds and wealth management firms increased their stakes significantly in the fourth quarter or first quarter, though their absolute share counts remain very low, ranging from 7 to 97 shares. Amgen's stock traded at $364.17 on Tuesday, trading above its 50-day moving average of $348.38 but below its 200-day average of $350.78. The company maintains a market capitalization of $196.55 billion with a P/E ratio of 25.34 and a beta of 0.41. Financial metrics indicate a quick ratio of 1.01 and a current ratio of 1.26, while the debt-to-equity ratio stands at 5.65. Analyst sentiment remains mixed with a consensus target price of $356.62 and an average rating of 'Hold.' Recent actions include Daiwa Securities Group lowering its price target to $390 with an 'outperform' rating, Argus decreasing its target to $375 but maintaining a 'buy' rating, and UBS raising its target to $420 with a 'buy' rating. Insider trading activity saw SVP Nancy A. Grygiel sell 1,237 shares in May for approximately $400,454.